A Phase 1/2 Trial of VX-522 in People with Cystic Fibrosis
Phase 1/2
39
about 4.2 years
18–65
24 sites in AL, CA, CO +15
About this study
Researchers are testing the safety and how well a treatment called VX-522 works in people with cystic fibrosis who haven't responded to other treatments. The trial will last for about 1535 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take IVA
- 2.Take VX-522 mRNA therapy
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Secondary: MAD: Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1), MAD: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Respiratory